Higher BMI Increases PCa Death Risk
ORLANDO—Elevated BMI is in-dependently associated with higher prostate cancer-specific mortality (PCSM) following radiation therapy and androgen suppression in men with locally advanced prostate cancer.
Prostate Cancer
Green Tea Adds to Anti-PCa Effect, Tests Show
Taking green tea together with low doses of a cyclooxygenase-2 (COX-2) inhibitor slows prostate cancer growth, laboratory tests show.
CRP Predicts Advanced PCa Outcomes
ORLANDO—Blood levels of C-reactive protein (CRP) independently predict survival in men with metastatic androgen-independent prostate cancer (AIPC), researchers conclude. CRP levels also predict the likelihood that patients will respond to therapy.
Neoadjuvant PCa Therapy: An Update
In the PSA era, most men with newly diagnosed prostate cancer present with clinically localized disease and are curable with surgery or radiation.
Vacuum Device Stems Penile Shortening
Early intervention with a vacuum erection device (VED) after radical retropubic prostatectomy (RRP) may reduce the likelihood of penile shortening, a researcher concluded.
Screening Cuts Risk of Advanced PCa
Biennial PSA screening decreases the likelihood of being diagnosed with metastatic prostate cancer, but nearly doubles the chance of being diagnosed with prostate cancer of any type, a Swedish sudy found.
PSA Velocity A Better Predictor
Preoperative PSA velocity is more useful than PSA doubling time for predicting outcomes after radical prostatectomy for prostate cancer, according to researchers.
Lower PSA Biopsy Threshold Advised
Diagnostic PSA levels in men younger than 50 years are significantly lower than guidelines suggest, according to researchers.
Fast Track for New Prostate Cancer Therapy
The FDA has assigned priority review status to the Biologics License Application for Provenge (sipuleucel-T), an investigational immunotherapy for asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer.
Drug for Baldness Affects PSA Testing
As little as 1 mg/day of finasteride can seriously distort the results of a PSA screening for prostate cancer, a recent study has found.
-
Loading...
-
Loading...
